English

Galmed Pharmaceuticals Ltd.

EDGAR

EOCN Report (type unavailable) · filed 2026-09-09

249 filing records in this dataset, filed from 2014-02-06 to 2026-09-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2019 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Cash and cash equivalents: 2.9 million USD 2026-06-30 Source
Exact value

2900000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 1 million shares 2026-06-30 Source
Exact value

1001394 shares

Reported share-count change

-81.12% · -4.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

5303050 shares · 2025-06-30· Source
1001394 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-11.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -1892000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -10309000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -5491000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -1910000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -2723000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-09.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2020-12-31
Operating income: 3 of 11 periods available· newest 2020-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2022-12-31
Total assets: 10 of 11 periods available· newest 2025-12-31
liabilities: No compatible figures in this window
Current assets: 10 of 11 periods available· newest 2025-12-31
Current liabilities: 10 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 10 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 2.79 million

Prior period

−USD 7.52 million

2024-01-01 – 2024-12-31
Current period

−USD 10.31 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-10309000 − -7517000 = -2792000 USD

-7517000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-10309000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Galmed Pharmaceuticals Ltd. · 2025-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Year-over-year change in Net income: -2792000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -10309000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#1993294 Filing: 000149315226014182 Input fundies:NetIncome: -7517000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#1993670 Filing: 000149315226014182
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 435,000

Prior period

−USD 5.88 million

2024-01-01 – 2024-12-31
Current period

−USD 6.32 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-6315000 − -5880000 = -435000 USD

-5880000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-6315000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Galmed Pharmaceuticals Ltd. · 2025-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Year-over-year change in Operating cash flow: -435000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -6315000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#2012941 Filing: 000149315226014182 Input fundies:OperatingCashFlow: -5880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#2013411 Filing: 000149315226014182
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ 0
Operating costs Derived Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ 30.21 million
Operating income −Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ 30.21 million
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow Unavailable An input is unavailable.
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	2038000	12753000 Derived	-10715000	Unavailable	Unavailable	Unavailable	Source 2018-01-01 – 2018-12-31: 2038000 Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ Inspect Revenue Open source 2018-01-01 – 2018-12-31: -10715000 Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ Inspect Operating Income Open source
2019 2019-01-01 – 2019-12-31	0	22376000 Derived	-22376000	Unavailable	Unavailable	Unavailable	Source 2019-01-01 – 2019-12-31: 0 Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ Inspect Revenue Open source 2019-01-01 – 2019-12-31: -22376000 Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ Inspect Operating Income Open source
2020 2020-01-01 – 2020-12-31	0	30210000 Derived	-30210000	Unavailable	Unavailable	Unavailable	Source 2020-01-01 – 2020-12-31: 0 Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ Inspect Revenue Open source 2020-01-01 – 2020-12-31: -30210000 Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ Inspect Operating Income Open source

Amounts are exact, in Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ 0 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ)	Source evidence
20182018-12-31	Revenue	2038000	Revenue: 2038000 Open source
20192019-12-31	Revenue	0	Revenue: 0 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 2038000 Open source
20192019-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 2038000 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -525.8% 2018

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	-525.8%	Operating Income: -10715000 Open source Revenue: 2038000 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: -22376000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -30210000 Open source Revenue: 0 Open source
2018-12-31	Net margin	Not reported	Revenue: 2038000 Open source
2019-12-31	Net margin	Not reported	Revenue: 0 Open source
2020-12-31	Net margin	Not reported	Revenue: 0 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 2038000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_bMMwq-iBQEmRBE6AIBuadQ)	Source evidence
20182018-12-31	Operating cash flow	Not reported	No source recorded
20192019-12-31	Operating cash flow	Not reported	No source recorded
20202020-12-31	Operating cash flow	Not reported	No source recorded

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Free cash flow	Unavailable	No source recorded
20192019-12-31	Free cash flow	Unavailable	No source recorded
20202020-12-31	Free cash flow	Unavailable	No source recorded

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Liabilities / assets	Not reported	No source recorded
2019-12-31	Liabilities / assets	Not reported	No source recorded
2020-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Current assets / current liabilities	Not reported	No source recorded
2019-12-31	Current assets / current liabilities	Not reported	No source recorded
2020-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	Unavailable Not reported for this period.	−USD 12.13 million Exact value Exact value: -12129000 USD 2016-01-01 – 2016-12-31: -12129000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2016-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -12129000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12129000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1410670 Filing: 000114420419013601 The citation records this snapshot. The page link may show a newer release later.	USD 17,000 Exact value Exact value: 17000 USD 2016-01-01 – 2016-12-31: 17000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Galmed Pharmaceuticals Ltd. · 2016-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Capital Expenditure: 17000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1411277 Filing: 000114420419013601 The citation records this snapshot. The page link may show a newer release later.	−USD 12.15 million Calculation and evidence -12129000 − 17000 USD Exact free cash flow: -12146000 USD 2016-01-01 – 2016-12-31: -12129000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 17000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Galmed Pharmaceuticals Ltd. · 2016-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Free cash flow: -12146000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12129000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1410670 Filing: 000114420419013601 Input fundies:CapitalExpenditure: 17000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1411277 Filing: 000114420419013601 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	Unavailable Not reported for this period.	−USD 12.07 million Exact value Exact value: -12067000 USD 2017-01-01 – 2017-12-31: -12067000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2017-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -12067000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12067000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1410465 Filing: 000114420419013601 The citation records this snapshot. The page link may show a newer release later.	USD 12,000 Exact value Exact value: 12000 USD 2017-01-01 – 2017-12-31: 12000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Galmed Pharmaceuticals Ltd. · 2017-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Capital Expenditure: 12000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1411076 Filing: 000114420419013601 The citation records this snapshot. The page link may show a newer release later.	−USD 12.08 million Calculation and evidence -12067000 − 12000 USD Exact free cash flow: -12079000 USD 2017-01-01 – 2017-12-31: -12067000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 12000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Galmed Pharmaceuticals Ltd. · 2017-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Free cash flow: -12079000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12067000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1410465 Filing: 000114420419013601 Input fundies:CapitalExpenditure: 12000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1411076 Filing: 000114420419013601 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	Unavailable Not reported for this period.	−USD 9.02 million Exact value Exact value: -9023000 USD 2018-01-01 – 2018-12-31: -9023000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2018-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -9023000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9023000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1410261 Filing: 000114420419013601 The citation records this snapshot. The page link may show a newer release later.	USD 90,000 Exact value Exact value: 90000 USD 2018-01-01 – 2018-12-31: 90000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Galmed Pharmaceuticals Ltd. · 2018-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Capital Expenditure: 90000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 90000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1410875 Filing: 000114420419013601 The citation records this snapshot. The page link may show a newer release later.	−USD 9.11 million Calculation and evidence -9023000 − 90000 USD Exact free cash flow: -9113000 USD 2018-01-01 – 2018-12-31: -9023000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 90000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Galmed Pharmaceuticals Ltd. · 2018-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Free cash flow: -9113000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9023000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1410261 Filing: 000114420419013601 Input fundies:CapitalExpenditure: 90000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/glmd-20181231.xml#1410875 Filing: 000114420419013601 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 20.46 million Exact value Exact value: -20461000 USD 2019-01-01 – 2019-12-31: -20461000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Galmed Pharmaceuticals Ltd. · 2019-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Net Income: -20461000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20461000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315222011729/form-20f.htm#2178876 Filing: 000149315222011729 The citation records this snapshot. The page link may show a newer release later.	−USD 14.94 million Exact value Exact value: -14937000 USD 2019-01-01 – 2019-12-31: -14937000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2019-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -14937000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14937000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315222011729/form-20f.htm#2212453 Filing: 000149315222011729 The citation records this snapshot. The page link may show a newer release later.	USD 12,000 Exact value Exact value: 12000 USD 2019-01-01 – 2019-12-31: 12000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Galmed Pharmaceuticals Ltd. · 2019-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Capital Expenditure: 12000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315222011729/form-20f.htm#2219290 Filing: 000149315222011729 The citation records this snapshot. The page link may show a newer release later.	−USD 14.95 million Calculation and evidence -14937000 − 12000 USD Exact free cash flow: -14949000 USD 2019-01-01 – 2019-12-31: -14937000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 12000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Galmed Pharmaceuticals Ltd. · 2019-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Free cash flow: -14949000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14937000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315222011729/form-20f.htm#2212453 Filing: 000149315222011729 Input fundies:CapitalExpenditure: 12000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315222011729/form-20f.htm#2219290 Filing: 000149315222011729 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 28.77 million Exact value Exact value: -28771000 USD 2020-01-01 – 2020-12-31: -28771000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Galmed Pharmaceuticals Ltd. · 2020-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Net Income: -28771000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28771000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315223009478/form20-f.htm#1919587 Filing: 000149315223009478 The citation records this snapshot. The page link may show a newer release later.	−USD 26.29 million Exact value Exact value: -26287000 USD 2020-01-01 – 2020-12-31: -26287000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2020-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -26287000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26287000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315223009478/form20-f.htm#1934388 Filing: 000149315223009478 The citation records this snapshot. The page link may show a newer release later.	USD 44,000 Exact value Exact value: 44000 USD 2020-01-01 – 2020-12-31: 44000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Galmed Pharmaceuticals Ltd. · 2020-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Capital Expenditure: 44000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 44000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315223009478/form20-f.htm#1936853 Filing: 000149315223009478 The citation records this snapshot. The page link may show a newer release later.	−USD 26.33 million Calculation and evidence -26287000 − 44000 USD Exact free cash flow: -26331000 USD 2020-01-01 – 2020-12-31: -26287000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 44000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Galmed Pharmaceuticals Ltd. · 2020-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Free cash flow: -26331000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26287000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315223009478/form20-f.htm#1934388 Filing: 000149315223009478 Input fundies:CapitalExpenditure: 44000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315223009478/form20-f.htm#1936853 Filing: 000149315223009478 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 32.47 million Exact value Exact value: -32467000 USD 2021-01-01 – 2021-12-31: -32467000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Galmed Pharmaceuticals Ltd. · 2021-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Net Income: -32467000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32467000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315224013203/form20-f.htm#2175204 Filing: 000149315224013203 The citation records this snapshot. The page link may show a newer release later.	−USD 32.89 million Exact value Exact value: -32892000 USD 2021-01-01 – 2021-12-31: -32892000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2021-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -32892000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32892000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315224013203/form20-f.htm#2203152 Filing: 000149315224013203 The citation records this snapshot. The page link may show a newer release later.	USD 11,000 Exact value Exact value: 11000 USD 2021-01-01 – 2021-12-31: 11000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Galmed Pharmaceuticals Ltd. · 2021-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Capital Expenditure: 11000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315224013203/form20-f.htm#2207996 Filing: 000149315224013203 The citation records this snapshot. The page link may show a newer release later.	−USD 32.9 million Calculation and evidence -32892000 − 11000 USD Exact free cash flow: -32903000 USD 2021-01-01 – 2021-12-31: -32892000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 11000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Galmed Pharmaceuticals Ltd. · 2021-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Free cash flow: -32903000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32892000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315224013203/form20-f.htm#2203152 Filing: 000149315224013203 Input fundies:CapitalExpenditure: 11000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315224013203/form20-f.htm#2207996 Filing: 000149315224013203 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 17.87 million Exact value Exact value: -17866000 USD 2022-01-01 – 2022-12-31: -17866000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Galmed Pharmaceuticals Ltd. · 2022-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Net Income: -17866000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17866000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000164117225002362/form20-f.htm#2007917 Filing: 000164117225002362 The citation records this snapshot. The page link may show a newer release later.	−USD 18.5 million Exact value Exact value: -18501000 USD 2022-01-01 – 2022-12-31: -18501000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2022-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -18501000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18501000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000164117225002362/form20-f.htm#2026837 Filing: 000164117225002362 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2022-01-01 – 2022-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Galmed Pharmaceuticals Ltd. · 2022-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000164117225002362/form20-f.htm#2029035 Filing: 000164117225002362 The citation records this snapshot. The page link may show a newer release later.	−USD 18.51 million Calculation and evidence -18501000 − 4000 USD Exact free cash flow: -18505000 USD 2022-01-01 – 2022-12-31: -18501000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Galmed Pharmaceuticals Ltd. · 2022-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Free cash flow: -18505000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18501000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000164117225002362/form20-f.htm#2026837 Filing: 000164117225002362 Input fundies:CapitalExpenditure: 4000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000164117225002362/form20-f.htm#2029035 Filing: 000164117225002362 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 6.91 million Exact value Exact value: -6912000 USD 2023-01-01 – 2023-12-31: -6912000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Galmed Pharmaceuticals Ltd. · 2023-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Net Income: -6912000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6912000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#1994043 Filing: 000149315226014182 The citation records this snapshot. The page link may show a newer release later.	−USD 6.14 million Exact value Exact value: -6137000 USD 2023-01-01 – 2023-12-31: -6137000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2023-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -6137000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6137000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#2013879 Filing: 000149315226014182 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 7.52 million Exact value Exact value: -7517000 USD 2024-01-01 – 2024-12-31: -7517000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Galmed Pharmaceuticals Ltd. · 2024-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Net Income: -7517000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7517000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#1993670 Filing: 000149315226014182 The citation records this snapshot. The page link may show a newer release later.	−USD 5.88 million Exact value Exact value: -5880000 USD 2024-01-01 – 2024-12-31: -5880000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2024-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -5880000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#2013411 Filing: 000149315226014182 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 10.31 million Exact value Exact value: -10309000 USD 2025-01-01 – 2025-12-31: -10309000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Galmed Pharmaceuticals Ltd. · 2025-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Net Income: -10309000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10309000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#1993294 Filing: 000149315226014182 The citation records this snapshot. The page link may show a newer release later.	−USD 6.32 million Exact value Exact value: -6315000 USD 2025-01-01 – 2025-12-31: -6315000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Galmed Pharmaceuticals Ltd. · 2025-12-31 Galmed Pharmaceuticals Ltd. (edgar:1595353) Operating Cash Flow: -6315000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595353/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6315000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595353/000149315226014182/form20-f.htm#2012941 Filing: 000149315226014182 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

249 filings · 1,328 latest values · 1,328 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001595353, 1595353, EOCN, GLMD, edgar:1595353

Also known as GALMED PHARMACEUTICALS LTD., GALMED PHARMACEUTICALS LTD., Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

Latest quarter

Revenue

Reported share-count change

Trailing twelve months

Net income

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation